1Ohmachi Y, Murata A, Matsuura N, et al. Specific expression of the pancreatic-secretory-trypsin-inhibitor (PSTI) gene in hepatocellular carcinoma [J]. Int J Cancer ,1993, 55:728-734.
2Marchbank T, Chinery R, Hanby AM, et al. Distribution and expression of pancreatic secretory trypsin inhibitor and its possible role in epithelial restitution[J]. Am J Pathol , 1996, 148:715 -722.
3Stenman UH, Koivunen E, Itkonen O. Biology and function of tumor.associated trypsin inhibitor, TATI[J]. Scand J Clin Lab Invest, 1991,51(Suppl 207) :5-9.
4Solakidi S, Dessypris A, Stathopoulos GP, et al. Tumour-associ ated trypsin inhibitor, carcinoembryonic antigen and actue-phase reactact proteins CRP and alphal-antitrypsin in patients with gastrointestinal malignancies[J]. Clin Biochem. 2004 Jan , 37(1):56-60.
5Ferdeghini M, Tramonti G, Donadio C, et al. Serum levels of tumor associated trypsin inhibitor (TATI) and glomerular filtration rate[J]. Unita di Nefrologia, Unversita di Pisa, Italy. RenFail, 1998 Mar, 20(2):295-302.
6Tramonti G, Ferdeghini M, Annichiarico C, et al. Assessment of tumor-associated trypsin inhibitor (TATI) as a marker of renal function[J]. J Nephrol, 2003 Sep-Oct, 16(5):663-72.
7Tramonti G, Ferdeghini M, Donadio C, et al. Renal function and serum concentration of five tumor markers (TATI, SCC, CYFRA 21-1, TPA, and TPS) in patients without evidence of neoplasia[J]. Cancer Detect Prey, 2000,24(1):86-90.
8Paju A, Jacobsen J, Rasmuson T, et al. Tumor-associated trypsin inhibitor as a prognostic factor in renal cell carcinoma[J]. J Urol , 2001,165(3): 959-962.
9Meria P, Toubert ME, Cussenot O, et al. Tumour-associated trypsin inhibitor and renal cell carcinoma[J]. Eur Urol , 1995,27:223-226.
10Venesmaa P. , Stenman UH. , Forss M. et al. Pre-operative ser um level of tumour-associated trypsin inhibitor and residual tumour size as prognostic indicators in stage Ⅲ epithelial ovarian cancer[J]. BrJ Obstet Gynaecol, 1998,105: 508.
